Merck to acquire Oncolmmune, accelerating development of COVID-19 treatment candidate

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Nov 23, 2020 at 10:52 AM.

  1. #1 cafead, Nov 23, 2020 at 10:52 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via Merck will acquire Oncolmmune for an upfront payment of $425m: pledging to accelerate the development of CD24Fc, a candidate for the treatment of patients with severe and critical COVID-19.

    article source
     
    Quote

Reply to Thread